Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: Focus on 24-h blood pressure control

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 5, 2010, Pages 301-313

  Parati, Gianfranco ^a   Ochoa, Juan Eugenio ^a   Ramos, Carlos ^a   Hoshide, Satoshi ^b   Lonati, Laura ^b   Bilo, Grzegorz ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Angiotensin II type 1 receptor blockers; Calcium channel blockers; Hypertension; Olmesartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MONOTHERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CIRCADIAN RHYTHM; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; IMIDAZOLES; SEVERITY OF ILLNESS INDEX; TETRAZOLES;

EID: 77957768665     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944710380228     Document Type: Review

References (68)

1. Bakris, G.L. ( 2008) Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 10(1 Suppl 1): 27-32.
2. Barrios, V., Brommer, P., Haag, U., Calderon, A. and Escobar, C. (2009) Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 29: 427-439.
3. Benetos, A., Thomas, F., Bean, K.E. and Guize, L. ( 2003) Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 21: 1635-1640.
4. Bilo, G., Giglio, A., Styczkiewicz, K., Caldara, G., Maronati, A., Kawecka-Jaszcz, K. et al. (2007) A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens 25: 2058-2066.
5. Bjorklund, K., Lind, L., Zethelius, B., Berglund, L. and Lithell, H. ( 2004) Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertens 22: 1691-1697.
6. Chrysant, S., Melino, M., Karki, S., Lee, J. and Heyrman, R. ( 2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30: 587-604.
7. Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J. and Heyrman, R. (2009) Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 11: 475-482.
8. Coca, A., Picado, M.J., de la Sierra, A., Aguilera, M.T., Sanchez, M., Lluch, M.M. et al. (1993) Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension. J Cardiovasc Pharmacol 22: 513-518.
9. Delgado-Mederos, R., Ribo, M., Rovira, A., Rubiera, M., Munuera, J., Santamarina, E. et al. (2008) Prognostic significance of blood pressure variability after thrombolysis in acute stroke. Neurology 71: 552-558.
10. Dolan, E., Stanton, A., Thijs, L., Hinedi, K., Atkins, N., McClory, S. et al. (2005) Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: The Dublin outcome study. Hypertension 46: 156-161.
11. Eguchi, K., Ishikawa, J., Hoshide, S., Pickering, T.G., Schwartz, J.E., Shimada, K. et al. (2009) Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens 22: 46-51.
12. Eto, M., Toba, K., Akishita, M., Kozaki, K., Watanabe, T., Kim, S. et al. (2005) Impact of blood pressure variability on cardiovascular events in elderly patients with hypertension. Hypertens Res 28: 1-7.
13. Ezzati, M., Lopez, A.D., Rodgers, A., Vander Hoorn, S. and Murray, C.J. ( 2002) Selected major risk factors and global and regional burden of disease. Lancet 360: 1347-1360.
14. Fabia, M.J., Abdilla, N., Oltra, R., Fernandez, C. and Redon, J. ( 2007) Antihypertensive activity of angiotensin II AT 1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 25: 1327-1336.
15. Frattola, A., Parati, G., Cuspidi, C., Albini, F. and Mancia, G. ( 1993) Prognostic value of 24-hour blood pressure variability. J Hypertens 11: 1133-1137.
16. Giles, T.D. ( 2006) Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens 24(Suppl): S11-S16.
17. Gosse, P., Lasserre, R., Minifie, C., Lemetayer, P. and Clementy, J. ( 2004) Blood pressure surge on rising. J Hypertens 22: 1113-1118.
18. Hasler, C., Nussberger, J., Maillard, M., Forclaz, A., Brunner, H.R. and Burnier, M. ( 2005) Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 78: 501-507.
19. Heagerty, A.M., Laeis, P. and Haag, U. ( 2009) Olmesartan medoxomil / amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy - additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens 27(Suppl 4): S283.
20. Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417-2428.
21. Jamerson, K.A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. ( 2004) Initial angiotensin-converting enzyme inhibitor / calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 17: 495-501.
22. Jinno, T., Iwai, M., Li, Z., Li, J.M., Liu, H.W., Cui, T.X. et al. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT 1 receptor blocker olmesartan. Hypertension 43: 263-269.
23. Kario, K., Pickering, T.G., Umeda, Y., Hoshide, S., Hoshide, Y., Morinari, M. et al. (2003) Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 107: 1401-1406.
24. Kikuya, M., Hozawa, A., Ohokubo, T., Tsuji, I., Michimata, M., Matsubara, M. et al. (2000) Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension 36: 901-906.
25. Kikuya, M., Ohkubo, T., Metoki, H., Asayama, K., Hara, A., Obara, T. et al. (2008) Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: The Ohasama study. Hypertension 52: 1045-1050.
26. Lawes, C.M., Vander Hoorn, S. and Rodgers, A. ( 2008) Global burden of blood-pressure-related disease, 2001. Lancet 371: 1513-1518.
27. Mancia, G., Bertinieri, G., Grassi, G., Parati, G., Pomidossi, G., Ferrari, A. et al. (1983) Effects of blood-pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 2: 695-698.
28. Mancia, G., Bombelli, M., Facchetti, R., Madotto, F., Corrao, G., Trevano, F.Q. et al. (2007 a) Long-term prognostic value of blood pressure variability in the general population: Results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 49: 1265-1270.
29. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007 b) 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462-1536.
30. Mancia, G., Di Rienzo, M. and Parati, G. ( 1993) Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension 21: 510-524.
31. Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J. et al. (2009) Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 27: 2121-2158.
32. Mena, L., Pintos, S., Queipo, N.V., Aizpurua, J.A., Maestre, G. and Sulbaran, T. ( 2005) A reliable index for the prognostic significance of blood pressure variability. J Hypertens 23: 505-511.
33. Neutel, J.M., Kereiakes, D.J., Punzi, H., Shojaee, A., Waverczak, W.F., Dubiel, R. et al. (2009 a) Efficacy and safety of an amlodipine (AML)/olmesartan medoxomil (OLM)-based titration regimen on blood pressure (BP) assessed by mean 24 hr ambulatory BP monitoring (ABPM) in patients with hypertension. J Clin Hypertens (Greenwich) 11: A129-A130.
34. Neutel, J.M., Littlejohn III, T., Shojaee, A., Waverczak, W.F., Dubiel, R. and Xu, J. ( 2009b) 24 hour efficacy of an amlodipine (AML)/olmesartan medoxomil (OM)-based titration regimen on blood pressure (BP) at daytime, nighttime and last 6, 4, 2 hours of dosing interval. J Clin Hypertens (Greenwich) 11: A130.
35. Oparil, S., Lee, J., Karki, S. and Melino, M. (2009) Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol 54: 427-436.
36. Palatini, P. ( 2005) Combination therapy in the management of hypertension: Focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich) 7: 96-101.
37. Palatini, P., Dorigatti, F., Mugellini, A., Spagnuolo, V., Vari, N., Ferrara, R. et al. (2004) Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: Insights from the Val-Syst Study. Clin Ther 26: 1436-1445.
38. Palatini, P., Penzo, M., Racioppa, A., Zugno, E., Guzzardi, G., Anaclerio, M. et al. (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152: 1855-1860.
39. Parati, G. ( 2005) Blood pressure variability: Its measurement and significance in hypertension. J Hypertens 23(Suppl): S19-S25.
40. Parati, G. and Bilo, G. ( 2008) Clinical relevance of day-by-day blood pressure and heart rate variability: New information from home self-measurements. Hypertension 52: 1006-1008.
41. Parati, G. and Bilo, G. ( 2009) Olmesartan medoxomil / amlodipine improves blood pressure control throughout 24 hours as compared to amlodipine monotherapy in patients with moderate-to-severe hypertension. Poster presented at: The 2nd International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes mellitus, Valencia.
42. Parati, G., Omboni, S., Albini, F., Piantoni, L., Giuliano, A. and Revera, M. (2009 a) Home blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare study. J Hypertens 27: 198-203.
43. Parati, G., Omboni, S. and Bilo, G. (2009 b) Why is out-of-office blood pressure measurement needed? Home blood pressure measurements will increasingly replace ambulatory blood pressure monitoring in the diagnosis and management of hypertension. Hypertension 54: 181-187.
44. Parati, G., Omboni, S., Rizzoni, D., Agabiti-Rosei, E. and Mancia, G. ( 1998) The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 16: 1685-1691.
45. Parati, G. and Pickering, T.G. (2009) Home blood-pressure monitoring: US and European consensus. Lancet 373: 876-878.
46. Parati, G., Pomidossi, G., Albini, F., Malaspina, D. and Mancia, G. ( 1987) Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5: 93-98.
47. Parati, G., Stergiou, G.S., Asmar, R., Bilo, G., de Leeuw, P., Imai, Y. et al. (2008) European Society of Hypertension guidelines for blood pressure monitoring at home: A summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 26: 1505-1526.
48. Parati, G. and Valentini, M. ( 2006) Prognostic relevance of blood pressure variability. Hypertension 47: 137-138.
49. Parati, G. and Valentini, M. ( 2007) Do we need out-of-office blood pressure in every patient ? Curr Opin Cardiol 22: 321-328.
50. Pereira, M., Lunet, N., Azevedo, A. and Barros, H. ( 2009) Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 27, (online early section).
51. Pickering, T.G. ( 2008) When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens 2: 119-124.
52. Pickering, T.G., Shimbo, D. and Haas, D. ( 2006) Ambulatory blood-pressure monitoring. N Engl J Med 354: 2368-2374.
53. Pierdomenico, S.D., Di Nicola, M., Esposito, A.L., Di Mascio, R., Ballone, E., Lapenna, D. et al. (2009) Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 22: 842-847.
54. Pringle, E., Phillips, C., Thijs, L., Davidson, C., Staessen, J.A., de Leeuw, P.W. et al. (2003) Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 21: 2251-2257.
55. Rosenthal, T. and Gavras, I. ( 2006) Fixed-drug combinations as first-line treatment for hypertension. Prog Cardiovasc Dis 48: 416-425.
56. Rothwell, P.M., Howard, S.C., Dolan, E., O'Brien, E., Dobson, J.E., Dahlof, B. et al. (2010) Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375: 895-905.
57. Sander, D., Kukla, C., Klingelhofer, J., Winbeck, K. and Conrad, B. ( 2000) Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation 102: 1536-1541.
58. Schillaci, G. and Parati, G. (2010) Determinants of blood pressure variability in youth: At the roots of hypertension. J Hypertens 28: 660-664.
59. Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G. et al. (2005) Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111: 1777-1783.
60. Staessen, J.A., Thijs, L., Fagard, R., O'Brien, E.T., Clement, D., de Leeuw, P.W. et al. (1999) Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282: 539-546.
61. Stumpe, K.O. ( 2004) Olmesartan compared with other angiotensin II receptor antagonists: Head-to-head trials. Clin Ther 26(Suppl A): A33-A37.
62. Tatasciore, A., Renda, G., Zimarino, M., Soccio, M., Bilo, G., Parati, G. et al. (2007) Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 50: 325-332.
63. Tozawa, M., Iseki, K., Yoshi, S. and Fukiyama, K. ( 1999) Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 14: 1976-1981.
64. Verdecchia, P., Angeli, F., Gattobigio, R., Rapicetta, C. and Reboldi, G. ( 2007) Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens 20: 154-161.
65. Volpe, M., Brommer, P., Haag, U. and Miele, C. (2009 a) Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 29: 11-25.
66. Volpe, M., Miele, C. and Haag, U. (2009 b) Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study. Clin Drug Investig 29: 381-391.
67. Wang, Y.R., Alexander, G.C. and Stafford, R.S. ( 2007) Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 167: 141-147.
68. Weir, M.R., Weber, M.A., Nesbitt, S.D., Hsueh, W.A., Neutel, J.M. and Jaffe, J. ( 2009) Rationale and design of the BP CRUSH study: Evaluating the efficacy and safety of amlodipine / olmesartan medoxomil in patients who are non-responders to antihypertensive mono- therapy. J Clin Hypertens 11: A137.